Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258388 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
A Phase 2 study of Prostate Cancer, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 13
- Study locations
NCT00258388: Completed Phase 2 study of Prostate Cancer, sponsored by NCIC Clinical Trials Group.
NCT00258388 is a Phase 2 study of Prostate Cancer that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 82 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 13 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00258388, a Phase 2 study of Prostate Cancer, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 13
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel and prednisone kill more tumor cells by making tumor cells less resistant to the drugs. PURPOSE: This randomized phase II trial is studying how well giving docetaxel and prednisone with or without OGX-011 works in treating patients with recurrent or metastatic prostate cancer that did not respond to previous hormone therapy.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG custirsen sodium
Study Locations (13)
Other
- Tom Baker Cancer Centre - Calgary
- Cross Cancer Institute - Edmonton
- QEII Health Sciences Center - Halifax
- Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
- BCCA - Cancer Centre for the Southern Interior - Kelowna
- London Regional Cancer Program - London
- CHUM - Hopital Notre-Dame - Montreal
- Atlantic Health Sciences Corporation - Saint John
- Odette Cancer Centre - Toronto
- Univ. Health Network-Princess Margaret Hospital - Toronto
- BCCA - Vancouver Cancer Centre - Vancouver
- CancerCare Manitoba - Winnipeg
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2005-09-28 |
| Est. Completion | 2011-01-18 |
| Phase | Phase 2 |
What the finished NCT00258388 record still lists
NCT00258388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which prednisone is the first listed.
NCT00258388 lists 13 locations in 2 states (Other, Washington).
Frequently Asked Questions
What is clinical trial NCT00258388 about?
NCT00258388 is a clinical study titled "Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy". RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel and prednisone kill more tumor cells by making tumor cells less resistant to th...
What is the current status of trial NCT00258388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2005-09-28. Estimated completion is 2011-01-18.
What conditions does trial NCT00258388 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00258388?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), custirsen sodium (DRUG).
Who is sponsoring clinical trial NCT00258388?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258388 being conducted?
This trial has 13 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00258388's enrollment target sits among peer trials
82 367th of 735 higher than 368 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI